Home Neuronal Signaling Dopamine Receptor agonist Bromocriptine Mesylate For research use only.

Bromocriptine Mesylate

Bromocriptine mesylate is a dopamine receptor agonist with a Ki of 12.2 nM for D3 receptor and D2 receptor and a Ki of 1659 nM, 59.7 nM, 1691 nM for D1 receptor, D4 receptor, and D5 receptor, respectively. Bromocriptine mesylate is used in the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions, and acromegaly.

Bromocriptine Mesylate Chemical Structure

Bromocriptine Mesylate Chemical Structure

CAS: 22260-51-1

Purity & Quality Control

Batch: Purity: 99.95%
99.95

Other Dopamine Receptor Products

Related compound libraries

Choose Selective Dopamine Receptor Inhibitors

Biological Activity

Description Bromocriptine mesylate is a dopamine receptor agonist with a Ki of 12.2 nM for D3 receptor and D2 receptor and a Ki of 1659 nM, 59.7 nM, 1691 nM for D1 receptor, D4 receptor, and D5 receptor, respectively. Bromocriptine mesylate is used in the treatment of Parkinson's disease, hyperprolactinemia-associated dysfunctions, and acromegaly.
Targets
D2 receptor [1] D3 receptor [1] D4 receptor [1] D1 receptor [1] D5 receptor [1]
12.2 nM(Ki) 12.2 nM(Ki) 59.7 nM(Ki) 1659 nM(Ki) 1691 nM(Ki)
In vitro
In vitro

Bromocriptine dose-dependently reduces the number of OH radicals. [1] Bromocriptine has a strong scavenging effect on the 5,5-dimethyl-1-pyrroline-N-oxide hydroxide signal produced from Fenton's reaction. Bromocriptine also attenuates the stable free radical diphenyl-p-picrylhydrazyl signal. [2]
In Vivo
In vivo

Bromocriptine (5 mg/kg, i.p., 7 days) completely protects against the decrease in mouse striatal dopamine and its metabolites induced by intraventricular injection of 6-hydroxydopamine after intraperitoneal administration of desipramine. [1] Bromocriptine (2.5 mg/kg, i.p., daily for 3 days) significantly reduces autooxidation of brain homogenates collected from rats. [2] Bromocriptine (12.5 mg/kg) produces mild dyskinesia over the course of the study that is significantly less severe than in the L-dopa-treated group in the MPTP-treated marmoset. Bromocriptine, has a lesser tendency than L-dopa to produce dyskinesia while similarly improving motor performance in drug-naive MPTP-treated marmosets. [3] Bromocriptine (10 μM and 10 mg/kg i.p.) blocks .OH formation caused by MPTP in vitro (20 μM) and in vivo (30 mg/kg i.p.) in mice. Bromocriptine reduces an MPTP-induced increase in the activity of catalase and superoxide dismutase in substantia nigra on the seventh day. Bromocriptine blocks MPTP-induced behavioral dysfunction as well as glutathione and dopamine depletion, indicating its potent neuroprotective action. [4]

Chemical lnformation & Solubility

Molecular Weight 750.7 Formula

C32H40BrN5O5.CH4O3S
CAS No. 22260-51-1 SDF Download Bromocriptine Mesylate SDF
Smiles CC(C)CC1N2C(=O)C(NC(=O)C3CN(C)C4CC5=C(Br)[NH]C6=C5C(=CC=C6)C4=C3)(OC2(O)C7CCCN7C1=O)C(C)C.C[S](O)(=O)=O
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Bromocriptine Mesylate | Bromocriptine Mesylate ic50 | Bromocriptine Mesylate price | Bromocriptine Mesylate cost | Bromocriptine Mesylate solubility dmso | Bromocriptine Mesylate purchase | Bromocriptine Mesylate manufacturer | Bromocriptine Mesylate research buy | Bromocriptine Mesylate order | Bromocriptine Mesylate mouse | Bromocriptine Mesylate chemical structure | Bromocriptine Mesylate mw | Bromocriptine Mesylate molecular weight | Bromocriptine Mesylate datasheet | Bromocriptine Mesylate supplier | Bromocriptine Mesylate in vitro | Bromocriptine Mesylate cell line | Bromocriptine Mesylate concentration | Bromocriptine Mesylate nmr